CorMedix, Inc.

CorMedix, Inc. is a biopharmaceutical company headquartered in Berkeley Heights, New Jersey, focused on the development and commercialization of therapeutic products for the prevention and treatment of life-threatening infectious and inflammatory diseases. The company's mission is centered on bringing novel and innovative treatments to market to improve patient quality of life, particularly in areas of high unmet medical need.

CorMedix's flagship product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution approved to reduce catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients using central venous catheters. The company commercially launched DefenCath for inpatient settings in April 2024 and for outpatient settings in July 2024. Following its acquisition of Melinta Therapeutics in August 2025, CorMedix expanded its portfolio to include a range of anti-infective products such as MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. The company also has a pipeline developing DefenCath for Total Parenteral Nutrition and pediatric hemodialysis populations, and is researching taurolidine-based therapies for rare pediatric cancers and antimicrobial medical devices.

Recent notable developments include the expansion of CEO Joseph Todisco's role to also include Chairman of the Board in January 2026, and the appointment of Mike Seckler as Executive Vice President and Chief Commercial Officer. CorMedix reported strong financial results for 2025, with significant revenue growth and net income, largely attributed to the successful commercialization of DefenCath and the integration of the Melinta Therapeutics acquisition. In April 2026, the company announced positive topline results from its Phase III ReSPECT trial assessing REZZAYO for the prophylaxis of invasive fungal diseases.